Who Paid My Doc
Lee Rosen
Santa Monica, CA Medical Doctor
NPI 1346295870 CMS profile 152140
2020 Santa Monica Blvd, Suite 510, Santa Monica, CA 90404
General payments
$585
Research payments
$11,753
Ownership & investment interest
$0
Research they led as principal investigator
$2,702,213
Through program year 2025, Lee Rosen of Santa Monica, CA is reported in the CMS Open Payments database as having received $585 across 7 general payments and $11,753 in research payments paid to them. Separately, studies naming them as principal investigator received $2,702,213 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $26 | 1 | |
| 2024 | Research | $4,600 | 2 | |
| 2023 | General | $33 | 1 | |
| 2023 | Research | $3,200 | 1 | |
| 2022 | General | $64 | 2 | |
| 2021 | Research | $1,282 | 1 | |
| 2020 | Research | $2,357 | 3 | |
| 2019 | General | $462 | 3 | |
| 2019 | Research | $313 | 1 |
Beside peers
- Lee Rosen
- California median
- Middle half of California
- National median
In program year 2025, general payments to Lee Rosen were reported at $26. Among 98,626 California profiles paid that year, the median was $172 and the middle half received between $54 and $610.
Show as a table
| Year | Lee Rosen | California median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $462 | $161 | $50–$652 | $163 |
| 2020 | $0 | $114 | $34–$392 | $114 |
| 2021 | $0 | $137 | $41–$509 | $132 |
| 2022 | $64 | $152 | $48–$573 | $149 |
| 2023 | $33 | $162 | $50–$581 | $160 |
| 2024 | $0 | $162 | $52–$583 | $164 |
| 2025 | $26 | $172 | $54–$610 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
43
Drug cost
$470,900
Branded share of claims
67.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Imbruvica Ibrutinib | Brand | 18 | $329,231 | |
| Braftovi Encorafenib | Brand | 11 | $141,448 | |
| Pantoprazole Sodium | Generic | 14 | $220 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 135 billing codesPaid by Medicare
$1,688,394
Medicare patients
330
Services billed
117,023
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 71% | |
| Cancer | 54% | |
| Arthritis | 48% | |
| Ischemic heart disease | 39% | |
| Diabetes | 38% | |
| Chronic kidney disease | 28% | |
| Depression | 26% | |
| Atrial fibrillation | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 | Office | 11 | 8,000 | $18,926 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 18 | 840 | $2,983 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram Q5101 | Office | 11 | 7,320 | $1,948 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 26 | 15,450 | $1,760 |
| Injection, irinotecan, 20 mg J9206 | Office | 11 | 772 | $1,720 |
| Injection, oxaliplatin, 0.5 mg J9263 | Office | 21 | 21,600 | $1,229 |
| Injection, fluorouracil, 500 mg J9190 | Office | 18 | 527 | $1,218 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 29 | 1,540 | $1,141 |
| Infusion, normal saline solution, 250 cc J7050 | Office | 56 | 557 | $290 |
| Injection, atropine sulfate, 0.01 mg J0461 | Office | 11 | 2,765 | $194 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.